FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients With Type 2 Diabetes
December 24, 2024
December 24, 2024
WASHINGTON, Dec. 24 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following news release on Dec. 23, 2024:
Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes as an adjunct to diet an . . .
Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes as an adjunct to diet an . . .